Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-05-11

Clinical Trial Update: JARDIANCE Regulartory Post Marketing Surveillance in Korean Type 2 Diabetes Mellitus

View source ↗

Summary

Post-marketing surveillance trial update for JARDIANCE in Korean adults with type 2 diabetes; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Jardiance (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Status: COMPLETED | Results posted: 2021-05-11